Sagent Pharmaceuticals (SGNT) Prices Up-Sized Offering at $16, High End of Range

April 20, 2011 9:39 AM EDT
Sagent Pharmaceuticals (Nasdaq: SGNT) priced an up-sized initial public offering of 5,750,000 shares of common stock at a price to the public of $16.00 per share, the high end of the expected $14-$16 range.

Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering.

Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hot IPOs, IPOs

Related Entities

Morgan Stanley, Jefferies & Co, Merrill Lynch, Bank of America

Add Your Comment